Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Related Citations for PubMed (Select 9627743)

1.

Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia.

Zorrilla EP, Cannon TD, Kessler J, Gur RE.

Biol Psychiatry. 1998 Jun 15;43(12):887-96.

PMID:
9627743
2.

Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?

Zorrilla EP, Cannon TD, Gur RE, Kessler J.

Biol Psychiatry. 1996 Nov 1;40(9):825-33.

PMID:
8896768
3.

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.

Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.

J Psychiatr Res. 2006 Oct;40(7):669-76. Epub 2006 Jun 9.

PMID:
16762371
4.

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.

Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H.

J Clin Psychiatry. 2006 Oct;67(10):1577-82.

PMID:
17107250
5.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

6.

Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.

Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, Zipursky R, Strakowski S, Sharma T, Kahn R, Gur R, Tollefson G; HGDH Research Group.

Br J Psychiatry. 2004 Jul;185:18-24.

7.

Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.

Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M.

Psychiatry Res. 2009 Jul 30;168(2):110-8. doi: 10.1016/j.psychres.2008.04.011. Epub 2009 Jun 6.

PMID:
19501918
8.

Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness.

Haas GL, Garratt LS, Sweeney JA.

J Psychiatr Res. 1998 May-Aug;32(3-4):151-9.

PMID:
9793868
9.

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J.

J Clin Psychiatry. 2006 Oct;67(10):1511-21.

PMID:
17107241
10.

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL.

J Clin Psychiatry. 2003 May;64(5):580-8.

PMID:
12755663
11.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
12.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
13.

One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.

Bachmann S, Bottmer C, Schroder J.

Psychopathology. 2008;41(2):115-23. Epub 2007 Dec 5.

PMID:
18059113
14.
15.

Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.

Lerner V, Miodownik C, Gibel A, Kovalyonok E, Shleifer T, Goodman AB, Ritsner MS.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):25-33. doi: 10.1097/WNF.0b013e31806450da.

PMID:
18303488
16.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW.

J Clin Psychiatry. 2006 Mar;67(3):453-60.

PMID:
16649833
17.
18.

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M.

Biol Psychiatry. 2005 Mar 15;57(6):577-85.

PMID:
15780844
19.

Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.

Hutton SB, Crawford TJ, Gibbins H, Cuthbert I, Barnes TR, Kennard C, Joyce EM.

Psychopharmacology (Berl). 2001 Sep;157(3):284-91.

PMID:
11605084
20.

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.

Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J.

Clin Ther. 2003 Feb;25(2):530-41.

PMID:
12749512
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk